INFORMATION DISCLOSU	RE
STATEMENT BY APPLICAL	٧ī
(Not for submission under 37 CFR 1.9	99)

Application Number		10587804
Filing Date		2007-06-07
First Named Inventor Bouqu		uin, T.
Art Unit		
Examiner Name		
Attorney Docket Number		0279us310

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of sited Desument		Releva	Columns,Lines where ant Passages or Relev s Appear	
	1									
If you wish	h to ac	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Lines where int Passages or Relev s Appear	
	1	20030124555	A1	2003-07	'-03	Brasch, et al.				
	2	20040106118	A1	2004-06	6-03	Kolmar, et al.				
	3	20020086427	A1	2002-07	'-04	Leiden, et al.				
If you wisl	h to ac	⊔ dd additional U.S. Publi	shed Ap	plication	citation	ı n information ı	olease click the Ade	d button	Add	
				FOREIG	3N PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	1162270	EP		A2	2001-12-12	SCRIPPS RESEAR	RCH		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10587804		
	Filing Date		2007-06-07		
	First Named Inventor Bouq		uin, T.		
	Art Unit				
	Examiner Name				
	Attorney Docket Numb	er	0279us310		

	2	1477808	EP	A1	2004-11-17	PROBIOGEN AG			
	3	2002034906	wo	A2	2002-05-02	GEORG AUGUST UNI GOETTINGEN			
	4	2003014361	wo	A1	2003-02-20	ALTANA PHARMA AG			
	5	2003099996	wo	A2	2003-12-04	Biogen, Inc.			
	6	2001044516	wo	A2	2001-06-21	Tularik Inc.			
lf you wis	h to a	dd additional Foreign P	atent Document	citation	information p	lease click the Add button	Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc),	the article (when appropr date, pages(s), volume-iss		T5	
	1	Abo T., et al. SsrA-med Escherichia coli. Genes			presence of m	iscoding drugs and its physic	ological role in		
	2		h engineered bac	terial-typ		lenocysteine-containing rat t nts and co-expression with t			
	3	Bedwell D.M., et al Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nature Med. 3:1280-1284, 1997.							
	4	Barton-Davis E.R., et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104:375-381, 1999.							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587804	
Filing Date		2007-06-07	
First Named Inventor	Bouq	uin, T.	
Art Unit			
Examiner Name			
Attorney Docket Numb	er	0279us310	

5	Burke J.F and Mogg, A.E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13 (17):6265-6272, 1985.	
6	Chang C.C., et al. Evolution of a cytokine using DNA family shuffling. Nat. Biotechnol. 17(8):793-797, 1999.	
7	Gorman C.M., et al. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11 (21):7631-7648, 1983.	
8	Howard M., et al. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 2:467-469, 1996.	
9	Hunt L., et al. Fluorescent proteins in animal cells for process development optimization of sodium butyrate treatment as an example. Biotechnol. Bioeng. 77(5):528-537, 2002.	
10	Ikezawa, H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull. 25 (4):409-417, 2002.	
11	Kawagishi J., et al. Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30 (2):224-232, 1995.	
12	Kozak, M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196(4):947-950, 1987.	
13	Kurtzman A., et al. Advances in directed protein evolution by recursive genetic recombination:applications to therapeutic proteins. Curr. Opin. Biotechnol. 12(4):361-370, 2001.	
14	Manuvakhova M., et al. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6(7):1044-1055, 2000.	
15	Millan, J.L. Molecular cloning and sequence analysis of human placental alkaline phosphatase. J. Biol. Chem. 261 (7):3112-3115, 1986.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.W./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

F

Α

Е Α

(Not for submission under 37 CFR 1.99)

pplication Number		10587804
ling Date		2007-06-07
rst Named Inventor Bouqu		uin, T.
rt Unit		
xaminer Name		
torney Docket Number		0279us310

	16	ack P., et al. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246:28-34, 995.	
	17	ack P., et al., Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell nsity fermentation of Escherichia coli. Biotechnol. 11:1271-1277, 1993.	
	18	ack P., and Plueckthun, A. Miniantibodies use of amphipathic helices to produce functional, flexibly linked dimeric FV agments with high avidity in Escherichia coli. Biochemistry 31:1579-1584, 1992	
	19	aimer E., et al. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 277 692):148-150, 1979.	
	20	ansfield I., et al. The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in accharomyces cerevisiae. EMBO J. 14:4365-4373, 1995.	
	21	halen R., et al. DNA shuffling and vaccines. Curr. Opin. Mol. Ther. 3 (1):31-36, 2001.	
	22	amauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 941):762-769, 2003.	
	23	nouravieva G., et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain lease factors, eRF1 and eRF3. EMBO J. 14(16):4065-4072, 1995.	
If you wisl	h to a	additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	
Examiner	Signa	e /Teresa Wessendorf/ Date Considered 9/13/10	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WiFO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached.